Logo

CSL Reports Top-line Data from the P-III (AEGIS-II) Study of CSL112 for Acute Myocardial Infarction (AMI)

Share this
CSL

CSL Reports Top-line Data from the P-III (AEGIS-II) Study of CSL112 for Acute Myocardial Infarction (AMI)

Shots:

  • CSL has reported top-line results from the P-III (AEGIS-II) study assessing the safety and efficacy of CSL112 vs PBO to reduce recurrent cardiovascular events at a duration of 90 days in patients (n=18,200) following AMI
  • The results revealed that the trial was unable to meet the 1EP of major adverse cardiovascular events (MACE) reduction at 90 days due to which no near-term regulatory filing is anticipated. Further analysis is in progress
  • CSL112 [Apolipoprotein A-I (Human)], a cholesterol efflux enhancer, is developed with a novel formulation of human plasma-derived Apolipoprotein A-I (apoA-I) that is the primary functional component of high-density lipoproteins (HDL)

Ref: CSL | Image: CSL

Related News:- CSL & Arcturus Therapeutics Receives MHLW Approval for ARCT-154 to Treat COVID in Adults

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions